Konruns Pharma's IPO plan aligned with policy

In line with Beijing's push for domestic innovation, the pharmaceutical firm aims to quintuple its product portfolio through in-house R&D and strategic acquisitions.

Konruns Pharma's IPO plan aligned with policy

Beijing Konruns Pharmaceutical is looking to capitalise on China's domestic innovation push by preparing an initial public offering to secure funding to develop new product lines for the country’s expanding drugs market.

A source familiar with the situation told FinanceAsia the proprietary drug maker is seeking to raise between $200 million to $300 million from the Hong Kong IPO primarily to finance research and development of new drugs.

Be fruitful and...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition